Sun yat-sen University Cancer Center
Guangzhou, Guangdong, 510000, China
NCT Number: NCT02606916
This Prospective, single-arm Phase Ⅱ study is to determine the efficacy and safety of Once-daily Simultaneous Modulated Accelerated Radiotherapy combined with S-1/DDP for geratic esophageal squamous cell carcinoma patients.
Looking for future studies?
Notify Me70 year–80 year
All sexes
Interventional
Phase 2
Guangzhou, Guangdong, 510000, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
DDP(25 mg/m2.qw) for six weeks.
S-1(40 mg/m2.Bid .po) on D1-14,D22-35 during radiotherapy
Time frame: 2-year
the percentage of patients who had partial remission or complete remission after chemoradiotherapy
Time frame: 3-year
Time frame: 3-year
Time frame: 1 year after radiochemotherapy
the percentage of patients who develop grade 3 or 4 toxicities during and 1 year after radiochemotherapy
Sun Yat-sen University
Other
A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06010303
Carcinoma, Carcinoma, Squamous Cell
Hefei, Anhui, China
View Trial DetailsNCT03322267
Carcinoma, Carcinoma, Squamous Cell
Taipei, Taiwan
View Trial DetailsNCT07363629
Carcinoma, Carcinoma, Squamous Cell
Shijiazhuang, Hebei, China
View Trial DetailsNCT04045496
Adenocarcinoma, Breast Cancer
Denver, Colorado, United States
View Trial Details